



# Vyvgart in India

The CDSCO named-patient coordination pathway — indicative 2026

NEUROLOGY · GENERALISED MYASTHENIA GRAVIS

## The clinical situation

Vyvgart (efgartigimod alfa-fcab) is an FDA-approved FcRn antagonist for generalised myasthenia gravis (gMG) in adults who are AChR-antibody positive, manufactured by argenx. The IV formulation is a one-hour infusion of 10 mg/kg once weekly for four weeks, with additional cycles scheduled by clinical response; a subcutaneous formulation (Vyvgart Hytrulo) is also available. India has a significant gMG patient population; conventional therapy (pyridostigmine, steroids, azathioprine, mycophenolate, rituximab, IVIG, plasma exchange) remains the backbone of care, but Vyvgart is increasingly sought in refractory or steroid-dependent disease. Eligibility requires confirmed AChR-antibody seropositivity, MGFA classification, and pre-treatment screening.

### The pathway, 6 steps

- 1 Consultation with neurology.** AChR-antibody confirmation, gMG diagnosis, MGFA classification, and pre-treatment screening documented.
- 2 Infusion facility identification.** A tertiary-care biologics-capable centre able to manage infusion reactions.
- 3 CDSCO personal-use application.** Physician or importing pharmacy files clinical letter, patient identifier, and product details.
- 4 US-side sourcing.** Reserve Meds coordinates through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Cold-chain shipment.** Vyvgart ships at 2–8°C with continuous temperature monitoring.
- 6 Arrival & cycle administration.** The licensed centre administers the four-weekly cycle; further cycles per clinical response.

### Indicative economics

**Reference US cash-pay range:** USD 400,000–600,000 annualised depending on cycle frequency (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first cycle, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review, keyed to the AChR-positive gMG rationale. **Logistics.** 2–8°C cold-chain coordination to the

licensed administration facility. **Concierge case lead.** Named point of contact across cycles. **We are a coordinator** — not the prescriber, not the dispensing pharmacy, not the infusion centre. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Vyvgart × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/vyvgart-india.html](https://reservemed.com/access-guides/vyvgart-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team